In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y. Kwong YD, Hsu CY. Ann Intern Med 2023;176:JC26.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kwong YD, Hsu CY. In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y. Ann Intern Med 2023;176:JC26.
PMID: 36877974